Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla. , Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel
Toggle Summary KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CELEBRATION, Fla. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022 , at 5:00 p.m. ET Perry Sternberg , Corium, Inc.’s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS ® Acquired substantially all the assets and operations of
Toggle Summary KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
CELEBRATION, Fla. , Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm to Report Second Quarter 2022 Financial Results
CELEBRATION, Fla. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
CELEBRATION, Fla. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
CELEBRATION, Fla. , July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc.  (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION, Fla. , June 01, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company),
Toggle Summary KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S.
Toggle Summary KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022 , at 5:00 p.m. ET Filed Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) for KP1077, a serdexmethylphenidate (SDX)-based product candidate for idiopathic